Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Research output: Contribution to journalArticle

Standard

Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. / Cazzaniga, Giovanni; de Lorenzo, Paola; Alten, Julia; Röttgers, Silja; Hancock, Jeremy; Saha, Vaskar; Castor, Anders; Madsen, Hans O.; Gandemer, Virginie; Cavé, Hélène; Leoni, Veronica; Köhler, Rolf; Ferrari, Giulia M.; Bleckmann, Kirsten; Pieters, Rob; Van Der Velden, Vincent; Stary, Jan; Zuna, Jan; Escherich, Gabriele; Stadt, Udo Zur; Aricò, Maurizio; Conter, Valentino; Schrappe, Martin; Valsecchi, Maria Grazia; Biondi, Andrea.

In: Haematologica, Vol. 103, No. 1, 01.01.2018, p. 107-115.

Research output: Contribution to journalArticle

Harvard

Cazzaniga, G, de Lorenzo, P, Alten, J, Röttgers, S, Hancock, J, Saha, V, Castor, A, Madsen, HO, Gandemer, V, Cavé, H, Leoni, V, Köhler, R, Ferrari, GM, Bleckmann, K, Pieters, R, Van Der Velden, V, Stary, J, Zuna, J, Escherich, G, Stadt, UZ, Aricò, M, Conter, V, Schrappe, M, Valsecchi, MG & Biondi, A 2018, 'Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies', Haematologica, vol. 103, no. 1, pp. 107-115. https://doi.org/10.3324/haematol.2017.176917

APA

CBE

Cazzaniga G, de Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, Van Der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A. 2018. Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 103(1):107-115. https://doi.org/10.3324/haematol.2017.176917

MLA

Vancouver

Author

Cazzaniga, Giovanni ; de Lorenzo, Paola ; Alten, Julia ; Röttgers, Silja ; Hancock, Jeremy ; Saha, Vaskar ; Castor, Anders ; Madsen, Hans O. ; Gandemer, Virginie ; Cavé, Hélène ; Leoni, Veronica ; Köhler, Rolf ; Ferrari, Giulia M. ; Bleckmann, Kirsten ; Pieters, Rob ; Van Der Velden, Vincent ; Stary, Jan ; Zuna, Jan ; Escherich, Gabriele ; Stadt, Udo Zur ; Aricò, Maurizio ; Conter, Valentino ; Schrappe, Martin ; Valsecchi, Maria Grazia ; Biondi, Andrea. / Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. In: Haematologica. 2018 ; Vol. 103, No. 1. pp. 107-115.

RIS

TY - JOUR

T1 - Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

AU - Cazzaniga, Giovanni

AU - de Lorenzo, Paola

AU - Alten, Julia

AU - Röttgers, Silja

AU - Hancock, Jeremy

AU - Saha, Vaskar

AU - Castor, Anders

AU - Madsen, Hans O.

AU - Gandemer, Virginie

AU - Cavé, Hélène

AU - Leoni, Veronica

AU - Köhler, Rolf

AU - Ferrari, Giulia M.

AU - Bleckmann, Kirsten

AU - Pieters, Rob

AU - Van Der Velden, Vincent

AU - Stary, Jan

AU - Zuna, Jan

AU - Escherich, Gabriele

AU - Stadt, Udo Zur

AU - Aricò, Maurizio

AU - Conter, Valentino

AU - Schrappe, Martin

AU - Valsecchi, Maria Grazia

AU - Biondi, Andrea

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged immunoglobulin/T-cell receptor genes (IG/TR) and/or BCR/ABL1 fusion transcript to investigate its predictive value in patients receiving Berlin-Frankfurt-Münster (BFM) high-risk (HR) therapy and post-induction intermittent imatinib (the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) study). MRD was monitored after induction (time point (TP)1), consolidation Phase IB (TP2), HR Blocks, reinductions, and at the end of therapy. MRD negativity progressively increased over time, both by IG/TR and BCR/ABL1. Of 90 patients with IG/TR MRD at TP1, nine were negative and none relapsed, while 11 with MRD<5×10−4 and 70 with MRD≥5×10−4 had a comparable 5-year cumulative incidence of relapse of 36.4 (15.4) and 35.2 (5.9), respectively. Patients who achieved MRD negativity at TP2 had a low relapse risk (5-yr cumulative incidence of relapse (CIR)=14.3[9.8]), whereas those who attained MRD negativity at a later date showed higher CIR, comparable to patients with positive MRD at any level. BCR/ABL1 MRD negative patients at TP1 had a relapse risk similar to those who were IG/TR MRD negative (1/8 relapses). The overall concordance between the two methods is 69%, with significantly higher positivity by BCR/ABL1. In conclusion, MRD monitoring by both methods may be functional not only for measuring response but also for guiding biological studies aimed at investigating causes for discrepancies, although from our data IG/TR MRD monitoring appears to be more reliable. Early MRD negativity is highly predictive of favorable outcome. The earlier MRD negativity is achieved, the better the prognosis.

AB - The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged immunoglobulin/T-cell receptor genes (IG/TR) and/or BCR/ABL1 fusion transcript to investigate its predictive value in patients receiving Berlin-Frankfurt-Münster (BFM) high-risk (HR) therapy and post-induction intermittent imatinib (the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) study). MRD was monitored after induction (time point (TP)1), consolidation Phase IB (TP2), HR Blocks, reinductions, and at the end of therapy. MRD negativity progressively increased over time, both by IG/TR and BCR/ABL1. Of 90 patients with IG/TR MRD at TP1, nine were negative and none relapsed, while 11 with MRD<5×10−4 and 70 with MRD≥5×10−4 had a comparable 5-year cumulative incidence of relapse of 36.4 (15.4) and 35.2 (5.9), respectively. Patients who achieved MRD negativity at TP2 had a low relapse risk (5-yr cumulative incidence of relapse (CIR)=14.3[9.8]), whereas those who attained MRD negativity at a later date showed higher CIR, comparable to patients with positive MRD at any level. BCR/ABL1 MRD negative patients at TP1 had a relapse risk similar to those who were IG/TR MRD negative (1/8 relapses). The overall concordance between the two methods is 69%, with significantly higher positivity by BCR/ABL1. In conclusion, MRD monitoring by both methods may be functional not only for measuring response but also for guiding biological studies aimed at investigating causes for discrepancies, although from our data IG/TR MRD monitoring appears to be more reliable. Early MRD negativity is highly predictive of favorable outcome. The earlier MRD negativity is achieved, the better the prognosis.

U2 - 10.3324/haematol.2017.176917

DO - 10.3324/haematol.2017.176917

M3 - Article

VL - 103

SP - 107

EP - 115

JO - Haematologica-The Hematology Journal

JF - Haematologica-The Hematology Journal

SN - 1592-8721

IS - 1

ER -